Latest news for UpHealth (OTC:UPHL) Stock

UpHealth Inc is a digital health company intent on creating a single, integrated platform of technologies and services essential to personalized, affordable, and effective care globally. The company's segment includes Integrated Care Management; Virtual Care Infrastructure; Services and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of its revenue from the Americas.

UpHealth Inc

Earnings

Earnings Beats

Earnings Misses

News

Telephone and Data Q4 2024 Adj. EPS $(0.09), Sales $1.240B Miss $1.254B Estimate

Canaccord Genuity analyst Kyle Rose maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $304 to $324.

Price Target

Analyst Ratings

PODD

Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $324

HC Wainwright &amp; Co. analyst Yi Chen maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Buy and lowers the price target from $23 to $20.

BLCO

HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Lowers Price Target to $20

Under the terms of the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027, for a potential total value of up to $9.84 per share in cash, subject to the tender of a majority of the outstanding shares of bluebird, receipt of applicable regulatory approvals, and other customary closing conditions.

BLUE

bluebird bio Agrees To Be Acquired By Carlyle And SK Capital For Potential Total Value Of Up To $9.84 Per Share In Cash

Piper Sandler analyst Brent Bracelin reiterates Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Overweight and maintains $53 price target.

Reiteration

KVYO

Piper Sandler Reiterates Overweight on Klaviyo, Maintains $53 Price Target

Piper Sandler analyst Arvind Ramnani maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Overweight and lowers the price target from $237 to $230.

GLOB

Piper Sandler Maintains Overweight on Globant, Lowers Price Target to $230

Pony AI Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) shares&nbsp;are trading&nbsp;higher&nbsp;premarket&nbsp;on Friday after the company launched paid robotaxi services connecting&nbsp;Guangzhou&#8217;s&nbsp;city center with Baiyun International Airpor<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43875974/pony-ai-inc-becomes-first-to-offer-robotaxi-operations-connecting-guangzhous-city-center-to-key-tr" rel="noreferrer noopener">t and South Railway Station</a>.
The company said it is the first and only approved to operate on these high-demand routes.
Pony.ai&#8217;s&nbsp;robotaxi service offers residents and tourists a seamless, autonomous travel option.&nbsp;Riders can book via the PonyPilot App, with fares matching standard Guangzhou taxi rates.&nbsp;
James Peng, co-founder and CEO of&nbsp;Pony.ai&nbsp;said,&nbsp;&#8220;By offering autonomous rides from the heart of the city to key transit hubs,&nbsp;we&#8217;re&nbsp;providing practical, real-world services which meet the needs of travellers and city residents alike, solidifying&nbsp;Pony.ai&#8217;stus&nbsp;as a global leader in the large-scale commercialization of autonomous mobility.&#8221;
Notably, Pony.ai has already launched paid robotaxi services at Beijing Daxing International Airport and Beijing South Railway Station.&nbsp;
Expanding in&nbsp;Guangzhou's&nbsp;city center and major transit points marks another key step in its autonomous mobility commercialization.
Last month, Pony.ai&nbsp;become&nbsp;the first company in China to secure approval for&nbsp;robotruck&nbsp;platooning tests on cross-provincial highways&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42996724/pony-ai-inc-becomes-the-first-company-in-china-approved-for-autonomous-truck-platooning-tests" rel="noreferrer noopener">linking Beijing, Tianjin, and Hebei</a>.&nbsp;
Also, in January, Pony.ai disclosed plans to introduce driverless transportation services at&nbsp;Hong Kong International Airport (HKIA),&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42867845/pony-ai-plans-to-provide-driverless-services-at-hong-kong-international-airport-hkia-with-plans-to" rel="noreferrer noopener">one of the&nbsp;world&#8217;s&nbsp;busiest airports</a>.&nbsp;
The company aims to expand its robotaxi services into urban Hong Kong over time.&nbsp;
Price Action: PONY shares are up 4.47% at $18.68 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43829965/black-sesame-emerges-as-dark-horse-in-driving-technology-race" target="_blank" rel="noreferrer noopener">Black Sesame emerges as dark horse in driving technology race</a></li>
</ul>
Photo via Shutterstock.

Equities

Mid Cap

Movers

PONY

Pony AI's Robotaxis Hit Guangzhou's High-Demand Routes: Details

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) with a Buy and maintains $9 price target.

MNOV

D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Onex (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ONEXF#OTC">ONEXF</a>) reported quarterly earnings of $0.62 per share. This is a 87.08 percent decrease over earnings of $4.80 per share from the same period last year. The company reported $99.00 million in sales this quarter. This is a 77.24 percent decrease over sales of $435.00 million the same period last year.

ONEXF

Onex Q4 Adj $0.62 Down From $4.80 YoY, Sales $99.00M Down From $435.00M YoY

Streaming service provider Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is doubling down on its commitment to Mexico&#8217;s audiovisual industry with a <a target="_blank" href="https://about.netflix.com/en/news/ted-sarandos-keynote-mexicos-presidency-press-conference" rel="noreferrer noopener">new $1 billion investment</a>.
In a statement from Co- CEO Ted Sarandos, the company emphasized its continued commitment to local content production.
The investment, set to take place over the next four years, aims to generate employment opportunities and stimulate audiovisual industry development throughout Mexico, underscoring Netflix&#8217;s enduring partnership with Mexican creatives, having been behind acclaimed projects such as Roma and Pedro Páramo.
In his keynote address at Mexico&#8217;s presidency press conference, Sarandos discussed Netflix&#8217;s long history of working with local talent.
&#8220;This country holds a special place in Netflix&#8217;s own history. It was here, 10 years ago, where we produced our first series outside of the United States called Club de Cuervos. We created it in Mexico for Mexico — and it paved the way for our programming strategy, which is all about local production,&#8221; said Sarandos.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43846469/walmart-q4-earnings-shine-but-soft-fy26-outlook-disappoints-street" rel="noreferrer noopener">Walmart Q4 Earnings Shine, But Soft FY26 Outlook Disappoints Street</a>
Since then, Netflix has earned several Academy Awards for Mexican-produced films, reinforcing its commitment to Mexico&#8217;s thriving creative industry.
Sarandos highlighted that each film and series made in Mexico collaborates with local production companies, providing significant benefits to the national economy.
For example, the production of Pedro Páramo added over 375 million pesos to Mexico&#8217;s GDP, created thousands of jobs, and supported traditional artisan skills.
The company has formed numerous local partnerships, producing hundreds of films and series that engage the community in various ways.
The company plans to collaborate with Churubusco Studios to enhance its facilities.
Price Action: NFLX shares closed lower by 1.80% at $1,024.54 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43819449/serve-robotics-rolls-out-autonomous-delivery-robots-in-miami-stocks-surge" target="_blank" rel="noreferrer noopener">Serve Robotics Rolls Into Miami&#8217;s Food Scene</a></li>
</ul>
Image via Shutterstock.

Entertainment

General

NFLX

Netflix Bets Big On Mexico: Plans $1B Investment To Supercharge Local Productions

Piper Sandler analyst Clarke Jeffries maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Overweight and raises the price target from $249 to $262.

Piper Sandler Maintains Overweight on Wix.com, Raises Price Target to $262

Rosenblatt analyst Steve Frankel maintains Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) with a Buy and maintains $15 price target.

UEIC

Rosenblatt Maintains Buy on Universal Electronics, Maintains $15 Price Target

UNH: -8% &#x7C; <a href="https://www.benzinga.com//node/43878094">Wall Street Journal Reported DOJ Launches Investigation Into UnitedHealth Group's Medicare Billing Practices, Citing Sources</a>
&nbsp;
CELH: 40% &#x7C; <a href="https://www.benzinga.com//node/43867833">Celsius Holdings shares are trading higher after the company announced it will acquire Alani Nu for $1.65 billion.</a>
&nbsp;
NAAS: 105% &#x7C; <a href="https://www.benzinga.com//node/43877006">NaaS Technology Announces $10 Million Share Repurchase Program Effective February 21, 2025, To Last Through February 2026</a>

Trading Ideas

CELH

NAAS

Market-Moving News for February 21st

Rosenblatt analyst Catharine Trebnick maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Buy and lowers the price target from $225 to $200.

NICE

Rosenblatt Maintains Buy on NICE, Lowers Price Target to $200

Needham analyst David Saxon maintains iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) with a Buy and raises the price target from $125 to $138.

IRTC

Needham Maintains Buy on iRhythm Technologies, Raises Price Target to $138

TMUS

T-Mobile Launches Essentials First Responder And Essentials Military Plans, Offering Exclusive Connectivity And Savings For Service Members

Rosenblatt analyst Catharine Trebnick maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Buy and lowers the price target from $45 to $40.

Rosenblatt Maintains Buy on RingCentral, Lowers Price Target to $40

ATRO

Astronics Corporation Ordered To Pay $11.9M In Patent Infringement Case With Lufthansa Technik, Final Liability Expected In Q2 2025

Emera (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EMA#TSX">EMA</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.77 by 9.09 percent. This is a 33.33 percent increase over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $1.76 billion which missed the analyst consensus estimate of $2.02 billion by 12.72 percent. This is a 10.60 percent decrease over sales of $1.97 billion the same period last year.

TSX:EMA

Emera Q4 Adj $0.84 Beats $0.77 Estimate, Sales $1.76B Miss $2.02B Estimate

Press Releases

UpHealth Completes Sale of Cloudbreak Health at $180 Million Full Cash Deal

Legal

The International Court of Arbitration awarded UpHealth Holdings more than $110 Million in Damages in Breach of Contract Lawsuit Involving the 2020 Purchase by UpHealth of Glocal Healthcare Systems

Health Care

UpHealth Provides Corporate Update and Announces Fourth Quarter and Full Year 2023 Financial Results

UpHealth Holdings Takes Steps to Enforce the International Court of Arbitration's Final Award to UpHealth Holdings of more than $110 Million in Damages in Breach of Contract Lawsuit Involving the 2020 Purchase by UpHealth of Glocal Healthcare Systems

Calcutta High Court rules in favour of UpHealth Holdings, Inc., and vigorously reinforces the ICC International Court of Arbitration previous $110 million award against Glocal directors and other Respondents, calling their conduct "dishonest and fraudulent"

Small Cap

UpHealth Holdings, Inc. Wins Ruling in Calcutta High Court, Mandating All Glocal Healthcare Respondents Submit Affidavits of Assets

UPHL

UpHealth

Jay Jennings Appointed Acting Chief Executive Officer of UpHealth; Replacing Martin BeckAnnounces the Promotion of Lisa Fluxman to President of TTC HealthcareReaffirms Jeremy Livianu as Chief Legal Officer and Secretary of UpHealthDELRAY BEACH, Fla., July 15, 2024 /PRNewswire/ -- UpHealth, Inc. ("UpHealth," the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPH#NYSE">UPH</a>), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced the July 11, 2024 appointment by the Board of Directors of the Company of Jay Jennings, currently the Company's Chief Financial Officer, to serve as the Company's Acting Chief Executive Officer, replacing Martin Beck, who resigned as Chief Executive Officer effective July 10, 2024. Mr. Beck also resigned from his position as a Class I director of the Company effective July 10, 2024. On July 11, 2024, the Board determined that it would not appoint any successor to fill the vacancy created by Mr. Beck's resignation as a Class I director at this time.

Comments

UpHealth

News

Latest news for UpHealth (OTC:UPHL) Stock

Monday, July 15, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga